## Current worldwide clinical trials on COVID-19

[dimensions.ai](https://dimensions.ai) provides a [daily updated list](https://docs.google.com/spreadsheets/d/1-kTZJZ1GAhJ2m4GAIhw1ZdlgO46JpvX0ZQa232VWRmw/edit#gid=1410737911) of clinical trials for COVID-19. 

## Analysis of Clinical Trial Data

Using [dimensions.ai](https://dimensions.ai) service and simple NLP scripts, the following figures show the distribution of COVID-19 clinical trials around the world and the different types of trials. The statistics will be updated daily. 

![countries](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/figure_countries.png)

![types_of_trials](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/figure_types.png)

Similarily, using the same data, a preliminary small molecule drug list with clinical trial counts was automatically generated using relevant key words. This list is only an estimate and will be updated weekly.

![therapeutics_trials](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/figure_drugs_treatment.png)



## Selected Drug information of current ongoing clinical studies on COVID-19

The information below is collected from recent research articles, news articles, or clinical reports of COVID-19 studies contributed from various research groups worldwide. The source links or full article download are provided to facilitate your own investigation and research on these molecules. 


| Drug Name             | Structure                                                    | MoA                                                          | Indication                                                   | DrugBank URL                                                 | Anti-2019-nCoV Evidence                          | Reference                                                    |
| --------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------------------------------- | ------------------------------------------------------------ |
| Remdesivir            | ![img3](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_remdesivir.png) | RNA  polymerase inhibitor                                    | Anti-Ebola passed Phase III, COVID-19 Phase III              | [DB14761](https://www.drugbank.ca/drugs/DB14761)             | In Vitro Assay, Clinical report, Clinical trial | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [8](https://www.nejm.org/doi/10.1056/NEJMoa2001191); [14](http://clarivate.com.cn/coronavirus-resources/images/Remdesivir.pdf); [15](https://www.nature.com/articles/s41422-020-0282-0); [16](https://clinicaltrials.gov/ct2/show/NCT04257656) |
| Lopinavir             | ![img1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_lopinavir.png) | Protease inhibitor                                           | Anti-HIV approved, COVID-19                                  | [DB01601](https://www.drugbank.ca/drugs/DB01601)             | Clinical Trial                                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Ritonavir             | ![img2](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ritonavir.png) | Protease inhibitor                                           | Anti-HIV approved, COVID-19                                  | [DB00503](https://www.drugbank.ca/drugs/DB00503)             | Clinical Trial                                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml); [6](http://www.chictr.org.cn/showprojen.aspx?proj=48782) |
| Emtricitabine         | ![img13](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_emtricitabine.png) | nucleoside reverse  transcriptase inhibitor                  | Anti-HIV  approved, anti-HBV                                 | [DB00879](https://www.drugbank.ca/drugs/DB00879)             | Clinical Trial                                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Tenofovir             | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_tenofovir.png) | nucleoside reverse  transcriptase inhibitor                  | Anti-HIV Phase III, anti-HBV                                 | [DB14126](https://www.drugbank.ca/drugs/DB14126)             | Clinical Trial                                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Ribavirin             | ![img12](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ribavirin.png) | viral mRNA and  protein synthesis inhibitor                  | Anti-HCV,  Anti-HBV, Anti-SARS, Anti-influenza, COVID-19     | [DB00811](https://www.drugbank.ca/drugs/DB00811)             | Clinical Trial                                  | [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782)     |
| Umifenovir            | ![img5](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_arbidol.png) |                                                              | Influenza approved, COVID-19 Phase 4                         | [DB13609](https://www.drugbank.ca/drugs/DB13609)             | Clinical trial                                  | [9](https://clinicaltrials.gov/ct2/show/NCT04252885); [22](https://clinicaltrials.gov/ct2/show/NCT04255017) |
| Ruxolitinib           | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ruxolitinib.png) | KInase inhibitor                                             | COVID-19 Phase 0                                             | [DB08877](https://www.drugbank.ca/drugs/DB08877)             | Clinical Trial                                  | [28](http://www.chictr.org.cn/showprojen.aspx?proj=49088)    |
| Favipiravir           | ![img6](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_favipiravir.png) | RNA polymerase inhibitor                                     | Anti-influenza approved, anti-Ebola Phase II                 | [DB12466](https://www.drugbank.ca/drugs/DB12466)             | Clinical Trial                                  | [10](http://www.xinhuanet.com/english/2020-02/01/c_138747115.htm); [18](http://www.chictr.org.cn/showprojen.aspx?proj=49042) |
| Darunavir             | ![img10](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_darunavir.png) | Protease inhibitor                                           | Anti-HIV approved                                            | [DB01264](https://www.drugbank.ca/drugs/DB01264)             | Clinical Trial                                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Cobicistat            | ![img11](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_cobicistat.png) |                                                              | Anti-HIV approved                                            | [DB09065](https://www.drugbank.ca/drugs/DB09065)             | Clinical trial                                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Methylprednisolone    | ![img9](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_methylprednisolone.png) | Corticosteroid                                               | COVID-19 Phase II, allergic asthma and rheumatic disorders approved | [DB00959](https://www.drugbank.ca/drugs/DB00959)             | Clinical Trial                                  | [12](http://www.chictr.org.cn/showprojen.aspx?proj=48777); [13](https://clinicaltrials.gov/ct2/show/NCT04244591) |
| Baloxavir marboxil    | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_baloxavirmarboxil.png) | Polymerase inhibitor                                         | anti-influenza approved                                      | [DB13997](https://www.drugbank.ca/drugs/DB13997)             | Clinical Trial                                  | [21](http://www.chictr.org.cn/showprojen.aspx?proj=49015)    |
| Oseltamivir           | ![img15](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_oseltamivir.png) | Neuraminidase inhibitor; Sialidase inhibitor                 | anti-influenza approved, COVID-19 Phase III                  | [DB00198](https://www.drugbank.ca/drugs/DB00198)             | Clinical Trial                                  | [22](https://clinicaltrials.gov/ct2/show/NCT04255017)        |
| IFN alpha-1b          |                                                              | Immunomodulation                                             | Interferon                                                   |                                                              | Clinical trial                                  | [5](http://www.chictr.org.cn/showproj.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Danoprevir            | ![img17](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_danoprevir.png) | Protease inhibitor                                           | anti-HCV Phase III, COVID-19 Phase 4                         | [DB11779](https://www.drugbank.ca/drugs/DB11779)             | Clinical Trial                                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748)    |
| Peginterferon alfa-2a |                                                              | Immunomodulation                                             | HCV approved, COVID-19 Phase 4                               | [DB00008](https://www.drugbank.ca/drugs/DB00008)             | Clinical trial                                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748)    |
| Chloroquine           | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_chloroquine.png) |                                                              | Antimalarial approved, anti-HIV phase III, anti-HCV, COVID-19 Phase  4 | [DB14761](https://www.drugbank.ca/drugs/DB14761)             | In Vitro Assay, Clinical trial                  | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [15](https://www.nature.com/articles/s41422-020-0282-0); [17](http://www.chictr.org.cn/showprojen.aspx?proj=48968) |
| Azvudine              | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_azuvudine.png) |                                                              | anti-HIV approved                                            | [PubChem 24769759](https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine) | Clinical trial                                  | [19](http://www.chictr.org.cn/showproj.aspx?proj=49532); [20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140803/) |
| Dipyridamole          | ![img20](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_dipyridamole.png) | Adenosine deaminase and phosphodiesterase inhibitor          | COVID-19 Phase 4; Phase 4 completed for stroke prevention; Phase 4 completed for coronary arteriosclerosis | [DB00975](https://www.drugbank.ca/drugs/DB00975)             | Clinical Trial                                  | [24](http://www.chictr.org.cn/showprojen.aspx?proj=49864); [25](https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf) |
| Thalidomide           | ![img23](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_thalidomide.png) |                                                              | COVID-19 Phase 2;  Phase 3 completed for cancers             | [DB01041](https://www.drugbank.ca/drugs/DB01041)             | Clinical Trial                                  | [26](https://clinicaltrials.gov/ct2/show/NCT04273529)        |
| Fingolimod            | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_fingolimod.png) |                                                              | COVID-19 Phase 2; Phase 4 completed for Multiple Sclerosis   | [DB08868](https://www.drugbank.ca/drugs/DB08868)             | Clinical Trial                                  | [27](https://clinicaltrials.gov/ct2/show/NCT04280588)        |
| Triazavirin           | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_triazavirin.png) | RNA synthesis inhibitor                                      | COVID-19 Phase 3                                             | [DB15622](https://www.drugbank.ca/drugs/DB15622)             | Clinical Trial                                  | [29](http://www.chictr.org.cn/showprojen.aspx?proj=49723)    |
| Tranilast             | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_tranilast.png) | Hematopoietic prostaglandin D synthase inhibitor             | Phase 4 completed for Conjunctivitis; COVID-19 Phase 4       | [DB07615](https://www.drugbank.ca/drugs/DB07615)             | Clinical Trial                                  | [30](http://www.chictr.org.cn/showprojen.aspx?proj=49738)    |
| Acetylcysteine        | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_acetylcysteine.png) | Mucolytic agent                                              | Phase 4 completed for Drug Overdose, AMI, Bipolar disorder, lung diseases; COVID-19 Phase 4 | [DB06151](https://www.drugbank.ca/drugs/DB06151)             | Clinical Trial                                  | [31](http://www.chictr.org.cn/showprojen.aspx?proj=50241)    |
| Ebastine              | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ebastine.png) | H1 inhibitor                                                | Phase 4 completed for IBS, urticaria; COVID-19 Phase 4       | [DB11742](https://www.drugbank.ca/drugs/DB11742)             | Clinical Trial                                  | [32](http://www.chictr.org.cn/showprojen.aspx?proj=49790)    |
| Losartan              | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_losartan.png) | Angiotensin II receptor blocker                              | Phase 4 completed for high blood pressure, hypertension, diabetes mellitus, kidney diseases, stroke; COVID-19 Phase 2 | [DB00678](https://www.drugbank.ca/drugs/DB00678)             | Clinical Trial                                  | [33](https://clinicaltrials.gov/ct2/show/NCT04311177)        |
| Pirfenidone           | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_pirfenidone.png) | Collagen synthesis inhibitor, Profibrotic cytokine down-regulator | Phase 4 completed for IPF; Phase 3 completed for DFU; COVID-19 Phase 0 | [DB04951](https://www.drugbank.ca/drugs/DB04951)             | Clinical Trial                                  | [34](http://www.chictr.org.cn/showprojen.aspx?proj=51416)    |
| Camostat              | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_camostat.png) |                                                              | COVID-19 Phase I                                             | [DB13737](https://www.drugbank.ca/drugs/DB13729)             | Clinical Trial                                  | [35](https://clinicaltrials.gov/ct2/show/NCT04321096)        |

---

<br>

<br>

<br>

Your [**feedback**](https://github.com/GHDDI-AILab/Targeting2019-nCoV/issues) is highly appreciated.

